Clinical Trial Update: Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction [Phase 3]

View source ↗

Summary

Phase 3 trial update for LCZ696 in Japanese patients with chronic heart failure with reduced ejection fraction (HF-rEF) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure With Reduced Ejection Fraction (HF-rEF) | Phase 3 | Status: COMPLETED | Results posted: 2023-12-08